Grimm MO, Smith M, Hussain M, Saad F, et al. Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial. Eur Urol 2025 Jun 20:S0302-2838(25)00340-9. doi: 10.1016/j.eururo.2025.
PMID: 40544121